Evidence map›Paper›PMID 41186229›Full record

ArticleAntimicrobial agents and chemotherapy2025

The lipoprotein biosynthesis pathway: key to OXA-mediated carbapenem resistance in

Jorgelina Morán-Barrio, Lucía Giacone, Luciano Brambilla, Carolina Fabbri, Alejandro M Viale

Abstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Identification and characterization of the functional LolB ortholog inbioRxiv : the preprint server for biology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jorgelina Morán-BarrioInstituto de Biología Molecular y Celular de Rosario (IBR, CONICET), Laboratorio de Resistencia a Antimicrobianos, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, Rosario, Argentina.ORCID 0000-0001-5952-9337
Lucía GiaconeInstituto de Biología Molecular y Celular de Rosario (IBR, CONICET), Laboratorio de Resistencia a Antimicrobianos, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, Rosario, Argentina.
Luciano BrambillaInstituto de Biología Molecular y Celular de Rosario (IBR, CONICET), Laboratorio de Resistencia a Antimicrobianos, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, Rosario, Argentina.
Carolina FabbriInstituto de Biología Molecular y Celular de Rosario (IBR, CONICET), Laboratorio de Resistencia a Antimicrobianos, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, Rosario, Argentina.
Alejandro M VialeInstituto de Biología Molecular y Celular de Rosario (IBR, CONICET), Laboratorio de Resistencia a Antimicrobianos, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, Rosario, Argentina.ORCID 0000-0002-1035-6479

Funding

Agencia Nacional de Promoción de la Investigación, el Desarrollo Tecnológico y la Innovación PICT2017-3536Agencia Santafesina de Ciencia, Tecnología e Innovación PEICID 2022-233
6 · The paper itself

Abstract

Carbapenem resistance in the gram-negative opportunistic pathogen

Indexed as

Acinetobacter baumanniiAnti-Bacterial AgentsBacterial Proteinsbeta-LactamasesCarbapenemsLipoproteinsMicrobial Sensitivity TestsMutagenesis, Site-DirectedAnti-Bacterial AgentsBacterial Proteinsbeta-lactamase OXA-58, Acinetobacter baumanniibeta-LactamasescarbapenemaseCarbapenemsLipoproteinscarbapenem-hydrolyzing class D β-lactamasescarbapenem-resistant Acinetobacter baumanniilipo-OXA carbapenemaseslipoprotein biosynthetic pathwaylipo-β-lactamasesouter membrane vesicles

Identifiers

PMID41186229
PMCPMC12691667

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.